ENDP Price Target Increased to $48 Thursday, April 14, 3:24 PM ET, by Market News Video Staff Today, Citigroup (C) raised its price target on shares of Endo Pharmaceuticals Inc. (ENDP) from ...
WPI Receives an Upgrade; Watson Large Holding of XPH ETF
By Market News Video Staff, Friday, November 5, 10:48 AM ET
Watson Pharmaceuticals (NYSE:WPI) was upgraded by UBS today to buy from neutral after announcing results yesterday. The firm raised their target price to $59 per share.
Watson had reported that net revenue grew 33% to $882.4 million, compared to $662.1 million in the third quarter 2009.On an adjusted cash basis, net income increased 18% to $105.9 million or $0.85 per share, compared to $90.0 million or $0.78 per share in the third quarter 2009.
The SPDR S&P Pharmaceuticals ETF (AMEX:XPH) counts WPI as a large holding at over 4.5% of the ETF. The iShares Dow Jones U.S. Pharmaceuticals Index Fund (AMEX:IHE) has Watson at 2.84% of its holdings and PowerShares Dynamic Pharmaceuticals Portfolio (AMEX:PJP) is 2.8% WPI.
This Article's Word Cloud:AMEXDynamicFundIndexJonesNYSEPharmaceuticalsPortfolioPowerSharesSPDRWatsonadjustedafterannouncingbasiscashcomparedcountsfirmfromgrewholdingholdingsiSharesincomeincreasedlargemillionneutraloverpricequarterraisedreportedresultsrevenuesharetargetthattheirthirdtodayupgradedyesterday
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.